首页 > 市场调查报告书 > 製药

癌症

市场调查报告书

商品编码

1534247

全球肾癌药物市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测

Global Kidney Cancer Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年07月01日 | 出版商:

Value Market Research | 英文 222 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球肾癌药物市场需求预计将从 2023 年的 67.2 亿美元达到近 116.1 亿美元的市场规模，2024-2032 年研究期间复合年增长率为 6.26%。

肾癌药物是指用于治疗肾癌（也称为肾细胞癌（RCC））的药物。这些药物包括旨在抑制肾臟癌细胞生长和扩散的标靶疗法、免疫疗法和化疗药物。标靶治疗通常会阻断参与癌细胞增殖和血管生成的特定分子，而免疫疗法则增强免疫系统识别和破坏癌细胞的能力。在某些情况下，化疗药物也可用于杀死快速分裂的癌细胞。治疗的选择取决于癌症分期、肿瘤中存在的基因突变以及患者的整体健康状况等因素。

市场动态

全球肾癌发生率不断上升，加上人们所认识的提高和早期检测工作的发展，正在推动对有效肾癌药物的需求。肾癌是全球十大最常见癌症之一，需要不断创新治疗方法以改善患者预后。分子生物学和基因分析的进步导致了专门针对与肾臟癌相关的分子改变的标靶疗法的发展。标靶治疗，包括酪胺酸激酶抑制剂 (TKI) 和哺乳动物雷帕霉素靶点 (mTOR) 抑制剂，已证明能够有效抑制晚期肾细胞癌患者的癌细胞生长并延长无恶化存活期。此外，免疫疗法彻底改变了肾臟癌的治疗模式，特别是释放免疫系统攻击癌细胞的检查点抑制剂。针对程序性细胞死亡蛋白1 (PD-1) 和细胞毒性T 淋巴细胞相关蛋白4 (CTLA-4) 的药物在临床试验中显示出良好的结果，为对传统治疗无反应的患者提供了新的治疗替代方案。此外，製药公司和研究机构之间的合作推动了肾癌药物开发的创新。合作伙伴关係的重点是识别新型生物标记、探索联合疗法以及进行临床试验，以扩大治疗选择并改善患者的治疗结果。然而，创新性肾癌药物的取得可能会受到监管障碍、报销政策和负担能力问题的限制，这可能会抑制市场成长。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球肾癌药物市场的各个细分市场进行了包容性评估。肾癌药物产业的成长和趋势为本研究提供了整体方法。

市场区隔

肾癌药物市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人群以及即将到来的机会。

按癌症类型

肾臟细胞癌（RCC）
移行细胞癌
肾母细胞瘤
肾臟肉瘤

透过治疗

标靶治疗
免疫疗法
化疗
其他疗法

按药物类别

血管新生抑制剂
单株抗体
马达抑制剂
细胞激素免疫疗法（IL-2）
其他药物类别

依给药途径

口服
静脉
皮下

按配销通路

医院药房
实体店面
电子商务

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲肾癌药物市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。肾臟癌药物市场的主要参与者包括 Active Biotech AB、Amgen Inc.、Astellas Pharma Inc.、AstraZeneca PLC、Bayer AG、Bristol-Myers Squibb Company、Eisai Co. Ltd.、Exelixis Inc.、F. Hoffmann-La罗氏有限公司、基因泰克公司、葛兰素史克公司、赫尔辛医疗保健公司、强生服务公司、默克公司、诺华公司。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

简介 - 市场动态
市场驱动因素
市场限制
机会
产业动态
波特五力分析
市场吸引力分析
- 按癌症类型分類的市场吸引力分析
- 按治疗方法进行的市场吸引力分析
- 按药品类别分類的市场吸引力分析
- 按给药途径进行的市场吸引力分析
- 按配销通路分類的市场吸引力分析
- 市场吸引力分析：按地区

第 4 章：价值链分析

价值链分析
原料分析
- 原料清单
- 原料厂商清单
- 主要原物料价格走势
潜在买家名单
行销管道
- 直效行销
- 间接行销
- 行销通路发展趋势

第 5 章：全球肾癌药物市场分析：按癌症类型

按癌症类型概述
按癌症类型进行历史和预测数据分析
肾臟细胞癌（RCC）
移行细胞癌
肾母细胞瘤
肾臟肉瘤

第 6 章：全球肾癌药物市场分析：依治疗方法

治疗概述
按治疗进行历史和预测数据分析
标靶治疗
免疫疗法
化疗
其他疗法

第 7 章：全球肾癌药物市场分析：依药物类别

按药物类别概述
按药物类别进行历史和预测数据分析
血管新生抑制剂
单株抗体
马达抑制剂
细胞激素免疫疗法（IL-2）
其他药物类别

第 8 章：全球肾癌药物市场分析：依给药途径

依给药途径概述
按给药途径进行历史和预测资料分析
口服
静脉
皮下

第 9 章：全球肾癌药物市场分析：按分销管道

配销通路概览
按配销通路进行历史和预测资料分析
医院药房
实体店面
电子商务

第 10 章：全球肾癌药物市场分析：依地理位置

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区按国家销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲按国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 11 章：肾癌药品公司的竞争格局

肾癌药物市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 12 章：公司简介

顶级公司市占率分析
市场集中度
Active Biotech AB

公司概况
公司收入
产品
最新动态

Amgen Inc.

公司概况
公司收入
产品
最新动态

Astellas Pharma Inc.

公司概况
公司收入
产品
最新动态

AstraZeneca PLC

公司概况
公司收入
产品
最新动态

Bayer AG

公司概况
公司收入
产品
最新动态

Bristol-Myers Squibb Company

公司概况
公司收入
产品
最新动态

Eisai Co. Ltd.

公司概况
公司收入
产品
最新动态

Exelixis Inc.

公司概况
公司收入
产品
最新动态

F. Hoffmann-La Roche Ltd.

公司概况
公司收入
产品
最新动态

Genentech Inc.

公司概况
公司收入
产品
最新动态

GSK Plc

公司概况
公司收入
产品
最新动态

Helsinn Healthcare SA

公司概况
公司收入
产品
最新动态

Johnson & Johnson Services Inc.

公司概况
公司收入
产品
最新动态

Merck & Co. Inc.

公司概况
公司收入
产品
最新动态

Novartis AG

公司概况
公司收入
产品
最新动态

註 - 在公司概况中，财务详细资讯和最新发展视情况而定，或对私人公司而言可能不包括在内

简介目录图表

Product Code: VMR112115310

The global demand for Kidney Cancer Drugs Market is presumed to reach the market size of nearly USD 11.61 Billion by 2032 from USD 6.72 Billion in 2023 with a CAGR of 6.26% under the study period 2024-2032.

Kidney cancer drugs refer to pharmaceutical agents used in the treatment of kidney cancer, also known as renal cell carcinoma (RCC). These drugs include targeted therapies, immunotherapies, and chemotherapy agents designed to inhibit the growth and spread of cancer cells in the kidneys. Targeted therapies typically block specific molecules involved in cancer cell proliferation and angiogenesis, while immunotherapies enhance the immune system's ability to recognize & destroy cancer cells. Chemotherapy drugs may also be used in certain cases to kill rapidly dividing cancer cells. The choice of treatment depends on factors such as cancer stage, genetic mutations present in the tumor, and the patient's overall health.

MARKET DYNAMICS

The rising incidence of kidney cancer globally, coupled with increasing awareness and early detection efforts, is driving demand for effective kidney cancer drugs. Kidney cancer is among the top ten most common cancers worldwide, necessitating continued innovation in treatment approaches to improve patient outcomes. Advancements in molecular biology and genetic profiling have led to the development of targeted therapies that specifically address molecular alterations associated with kidney cancer. Targeted therapies, including tyrosine kinase inhibitors (TKIs) & mammalian target of rapamycin (mTOR) inhibitors, have demonstrated efficacy in inhibiting cancer cell growth and prolonging progression-free survival in individuals diagnosed with advanced renal cell carcinoma. Moreover, immunotherapy has revolutionized the treatment landscape for kidney cancer, particularly checkpoint inhibitors that unleash the immune system to attack cancer cells. Drugs targeting programmed cell death protein 1 (PD-1) & cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) have shown promising results in clinical trials, offering new therapeutic alternatives for patients who do not respond to conventional treatments. Furthermore, collaborative efforts between pharmaceutical companies & research institutions drive innovation in developing kidney cancer drugs. Partnerships focus on identifying novel biomarkers, exploring combination therapies, and conducting clinical trials to expand treatment options and improve patient outcomes. However, access to innovative kidney cancer drugs can be limited by regulatory hurdles, reimbursement policies, and affordability issues, which may restrain market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Kidney Cancer Drugs. The growth and trends of Kidney Cancer Drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Kidney Cancer Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Cancer Type

Renal Cell Carcinoma (RCC)
Transitional Cell Cancer
Wilms Tumor
Renal Sarcoma

By Therapy

Targeted Therapy
Immunotherapy
Chemotherapy
Other Therapies

By Drug Class

Angiogenesis Inhibitors
Monoclonal Antibodies
Mtor Inhibitors
Cytokine Immunotherapy (IL-2)
Other Drug Classes

By Route of Administration

Oral
Intravenous
Subcutaneous

By Distribution Channel

Hospital Pharmacy
Brick and Mortar
E-Commerce

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Kidney Cancer Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Kidney Cancer Drugs market include Active Biotech AB, Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Eisai Co. Ltd., Exelixis Inc., F. Hoffmann-La Roche Ltd., Genentech Inc., GSK Plc, Helsinn Healthcare SA, Johnson & Johnson Services Inc., Merck & Co. Inc., Novartis AG. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. KIDNEY CANCER DRUGS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Cancer Type
- 3.7.2 Market Attractiveness Analysis By Therapy
- 3.7.3 Market Attractiveness Analysis By Drug Class
- 3.7.4 Market Attractiveness Analysis By Route of Administration
- 3.7.5 Market Attractiveness Analysis By Distribution Channel
- 3.7.6 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL KIDNEY CANCER DRUGS MARKET ANALYSIS BY CANCER TYPE

5.1. Overview By Cancer Type
5.2. Historical and Forecast Data Analysis By Cancer Type
5.3. Renal Cell Carcinoma (RCC) Historic and Forecast Sales By Regions
5.4. Transitional Cell Cancer Historic and Forecast Sales By Regions
5.5. Wilms Tumor Historic and Forecast Sales By Regions
5.6. Renal Sarcoma Historic and Forecast Sales By Regions

6. GLOBAL KIDNEY CANCER DRUGS MARKET ANALYSIS BY THERAPY

6.1. Overview By Therapy
6.2. Historical and Forecast Data Analysis By Therapy
6.3. Targeted Therapy Historic and Forecast Sales By Regions
6.4. Immunotherapy Historic and Forecast Sales By Regions
6.5. Chemotherapy Historic and Forecast Sales By Regions
6.6. Other Therapies Historic and Forecast Sales By Regions

7. GLOBAL KIDNEY CANCER DRUGS MARKET ANALYSIS BY DRUG CLASS

7.1. Overview By Drug Class
7.2. Historical and Forecast Data Analysis By Drug Class
7.3. Angiogenesis Inhibitors Historic and Forecast Sales By Regions
7.4. Monoclonal Antibodies Historic and Forecast Sales By Regions
7.5. Mtor Inhibitors Historic and Forecast Sales By Regions
7.6. Cytokine Immunotherapy (IL-2) Historic and Forecast Sales By Regions
7.7. Other Drug Classes Historic and Forecast Sales By Regions

8. GLOBAL KIDNEY CANCER DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

8.1. Overview By Route of Administration
8.2. Historical and Forecast Data Analysis By Route of Administration
8.3. Oral Historic and Forecast Sales By Regions
8.4. Intravenous Historic and Forecast Sales By Regions
8.5. Subcutaneous Historic and Forecast Sales By Regions

9. GLOBAL KIDNEY CANCER DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

9.1. Overview By Distribution Channel
9.2. Historical and Forecast Data Analysis By Distribution Channel
9.3. Hospital Pharmacy Historic and Forecast Sales By Regions
9.4. Brick and Mortar Historic and Forecast Sales By Regions
9.5. E-Commerce Historic and Forecast Sales By Regions

10. GLOBAL KIDNEY CANCER DRUGS MARKET ANALYSIS BY GEOGRAPHY

10.1. Regional Outlook
10.2. Introduction
10.3. North America Sales Analysis
- 10.3.1 Overview, Historic and Forecast Data Sales Analysis
- 10.3.2 North America By Segment Sales Analysis
- 10.3.3 North America By Country Sales Analysis
- 10.3.4 United States Sales Analysis
- 10.3.5 Canada Sales Analysis
- 10.3.6 Mexico Sales Analysis
10.4. Europe Sales Analysis
- 10.4.1 Overview, Historic and Forecast Data Sales Analysis
- 10.4.2 Europe By Segment Sales Analysis
- 10.4.3 Europe By Country Sales Analysis
- 10.4.4 United Kingdom Sales Analysis
- 10.4.5 France Sales Analysis
- 10.4.6 Germany Sales Analysis
- 10.4.7 Italy Sales Analysis
- 10.4.8 Russia Sales Analysis
- 10.4.9 Rest Of Europe Sales Analysis
10.5. Asia Pacific Sales Analysis
- 10.5.1 Overview, Historic and Forecast Data Sales Analysis
- 10.5.2 Asia Pacific By Segment Sales Analysis
- 10.5.3 Asia Pacific By Country Sales Analysis
- 10.5.4 China Sales Analysis
- 10.5.5 India Sales Analysis
- 10.5.6 Japan Sales Analysis
- 10.5.7 South Korea Sales Analysis
- 10.5.8 Australia Sales Analysis
- 10.5.9 South East Asia Sales Analysis
- 10.5.10 Rest Of Asia Pacific Sales Analysis
10.6. Latin America Sales Analysis
- 10.6.1 Overview, Historic and Forecast Data Sales Analysis
- 10.6.2 Latin America By Segment Sales Analysis
- 10.6.3 Latin America By Country Sales Analysis
- 10.6.4 Brazil Sales Analysis
- 10.6.5 Argentina Sales Analysis
- 10.6.6 Peru Sales Analysis
- 10.6.7 Chile Sales Analysis
- 10.6.8 Rest of Latin America Sales Analysis
10.7. Middle East & Africa Sales Analysis
- 10.7.1 Overview, Historic and Forecast Data Sales Analysis
- 10.7.2 Middle East & Africa By Segment Sales Analysis
- 10.7.3 Middle East & Africa By Country Sales Analysis
- 10.7.4 Saudi Arabia Sales Analysis
- 10.7.5 UAE Sales Analysis
- 10.7.6 Israel Sales Analysis
- 10.7.7 South Africa Sales Analysis
- 10.7.8 Rest Of Middle East And Africa Sales Analysis

11. COMPETITIVE LANDSCAPE OF THE KIDNEY CANCER DRUGS COMPANIES

11.1. Kidney Cancer Drugs Market Competition
11.2. Partnership/Collaboration/Agreement
11.3. Merger And Acquisitions
11.4. New Product Launch
11.5. Other Developments

12. COMPANY PROFILES OF KIDNEY CANCER DRUGS INDUSTRY

12.1. Top Companies Market Share Analysis
12.2. Market Concentration Rate
12.3. Active Biotech AB
- 12.3.1 Company Overview
- 12.3.2 Company Revenue
- 12.3.3 Products
- 12.3.4 Recent Developments
12.4. Amgen Inc.
- 12.4.1 Company Overview
- 12.4.2 Company Revenue
- 12.4.3 Products
- 12.4.4 Recent Developments
12.5. Astellas Pharma Inc.
- 12.5.1 Company Overview
- 12.5.2 Company Revenue
- 12.5.3 Products
- 12.5.4 Recent Developments
12.6. AstraZeneca PLC
- 12.6.1 Company Overview
- 12.6.2 Company Revenue
- 12.6.3 Products
- 12.6.4 Recent Developments
12.7. Bayer AG
- 12.7.1 Company Overview
- 12.7.2 Company Revenue
- 12.7.3 Products
- 12.7.4 Recent Developments
12.8. Bristol-Myers Squibb Company
- 12.8.1 Company Overview
- 12.8.2 Company Revenue
- 12.8.3 Products
- 12.8.4 Recent Developments
12.9. Eisai Co. Ltd.
- 12.9.1 Company Overview
- 12.9.2 Company Revenue
- 12.9.3 Products
- 12.9.4 Recent Developments
12.10. Exelixis Inc.
- 12.10.1 Company Overview
- 12.10.2 Company Revenue
- 12.10.3 Products
- 12.10.4 Recent Developments
12.11. F. Hoffmann-La Roche Ltd.
- 12.11.1 Company Overview
- 12.11.2 Company Revenue
- 12.11.3 Products
- 12.11.4 Recent Developments
12.12. Genentech Inc.
- 12.12.1 Company Overview
- 12.12.2 Company Revenue
- 12.12.3 Products
- 12.12.4 Recent Developments
12.13. GSK Plc
- 12.13.1 Company Overview
- 12.13.2 Company Revenue
- 12.13.3 Products
- 12.13.4 Recent Developments
12.14. Helsinn Healthcare SA
- 12.14.1 Company Overview
- 12.14.2 Company Revenue
- 12.14.3 Products
- 12.14.4 Recent Developments
12.15. Johnson & Johnson Services Inc.
- 12.15.1 Company Overview
- 12.15.2 Company Revenue
- 12.15.3 Products
- 12.15.4 Recent Developments
12.16. Merck & Co. Inc.
- 12.16.1 Company Overview
- 12.16.2 Company Revenue
- 12.16.3 Products
- 12.16.4 Recent Developments
12.17. Novartis AG
- 12.17.1 Company Overview
- 12.17.2 Company Revenue
- 12.17.3 Products
- 12.17.4 Recent Developments